Literature DB >> 19298493

The cost of multiple drug resistance in Pseudomonas aeruginosa.

H Ward1, G G Perron, R C Maclean.   

Abstract

The spread of bacterial antibiotic resistance mutations is thought to be constrained by their pleiotropic fitness costs. Here we investigate the fitness costs of resistance in the context of the evolution of multiple drug resistance (MDR), by measuring the cost of acquiring streptomycin resistance mutations (StrepR) in independent strains of the bacterium Pseudomonas aeruginosa carrying different rifampicin resistance (RifR) mutations. In the absence of antibiotics, StrepR mutations are associated with similar fitness costs in different RifR genetic backgrounds. The cost of StrepR mutations is greater in a rifampicin-sensitive (RifS) background, directly demonstrating antagonistic epistasis between resistance mutations. In the presence of rifampicin, StrepR mutations have contrasting effects in different RifR backgrounds: StrepR mutations have no detectable costs in some RifR backgrounds and massive fitness costs in others. Our results clearly demonstrate the importance of epistasis and genotype-by-environment interactions for the evolution of MDR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19298493     DOI: 10.1111/j.1420-9101.2009.01712.x

Source DB:  PubMed          Journal:  J Evol Biol        ISSN: 1010-061X            Impact factor:   2.411


  48 in total

1.  The costs of evolving resistance in heterogeneous parasite environments.

Authors:  Britt Koskella; Derek M Lin; Angus Buckling; John N Thompson
Journal:  Proc Biol Sci       Date:  2011-12-14       Impact factor: 5.349

2.  Bacterial recombination promotes the evolution of multi-drug-resistance in functionally diverse populations.

Authors:  Gabriel G Perron; Alexander E G Lee; Yun Wang; Wei E Huang; Timothy G Barraclough
Journal:  Proc Biol Sci       Date:  2011-11-02       Impact factor: 5.349

3.  Multidrug therapy and evolution of antibiotic resistance: when order matters.

Authors:  Gabriel G Perron; Sergey Kryazhimskiy; Daniel P Rice; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-22       Impact factor: 4.792

Review 4.  The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts.

Authors:  R Craig MacLean; Alex R Hall; Gabriel G Perron; Angus Buckling
Journal:  Nat Rev Genet       Date:  2010-06       Impact factor: 53.242

5.  Diminishing returns from beneficial mutations and pervasive epistasis shape the fitness landscape for rifampicin resistance in Pseudomonas aeruginosa.

Authors:  R C MacLean; G G Perron; A Gardner
Journal:  Genetics       Date:  2010-09-27       Impact factor: 4.562

Review 6.  Origin and proliferation of multiple-drug resistance in bacterial pathogens.

Authors:  Hsiao-Han Chang; Ted Cohen; Yonatan H Grad; William P Hanage; Thomas F O'Brien; Marc Lipsitch
Journal:  Microbiol Mol Biol Rev       Date:  2015-03       Impact factor: 11.056

7.  An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.

Authors:  Christopher M Oermann; George Z Retsch-Bogart; Alexandra L Quittner; Ronald L Gibson; Karen S McCoy; A Bruce Montgomery; Peter J Cooper
Journal:  Pediatr Pulmonol       Date:  2010-11

Review 8.  The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Borna Müller; Sonia Borrell; Graham Rose; Sebastien Gagneux
Journal:  Trends Genet       Date:  2012-12-13       Impact factor: 11.639

9.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

10.  Positive epistasis drives the acquisition of multidrug resistance.

Authors:  Sandra Trindade; Ana Sousa; Karina Bivar Xavier; Francisco Dionisio; Miguel Godinho Ferreira; Isabel Gordo
Journal:  PLoS Genet       Date:  2009-07-24       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.